Category: News & Comments
The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™
The Committee for Medicinal Products for Human Use (CHMP) announced a Positive Opinion recommending marketing authorization of Alnylam’s (ALNY) RNAi product Onpattro ™ (patisiran). The product is designed to treat hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy....
Read More
July 27, 2018
0
Why Amgen's Stock Is Up Over $11 Today
Amgen's Stock Is Up Amgen ( AMGN ) is speeding towards reaching its true, fair value. In the Q2 financial results Amgen has beaten the most optimistic analysts’ expectations and negative investors who keep mourning the firm’s 35 years...
Read More
August 9, 2019
0
A new European approval for Bristol-Myers’ immunotherapy opdivo. The future is starting now
The Future is Starting Now Recognizing that the future has already started now is important as it makes analysts use different criteria for the fair evaluation of the future growth of biotechnology startups and revenue-generating companies. This is our main...
Read More
July 31, 2018
0
The Beginning of a Nektar Outperformance?
Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics ( NKTR ) and Bristol-Myers Squibb ( BMY ) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar's bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into...
Read More
January 11, 2020
0
Why Akari Therapeutics Stock Price Rallied Today
Akari Therapeutics Stock Rallied Autoimmune and inflammatory disease treatments are works in progress with some approved products demonstrating remarkable efficacy. Still there are untreated inflammatory diseases, among them are those where the complement ( C5 ) and/or leukotriene ( LTB4...
Read More
August 14, 2019
0
AstraZeneca and Vertex Both Have Good News
AstraZeneca: Farxiga for Heart Failure with Reduced Ejection Fraction AstraZeneca ( AZN ) has good news. Many of them are extremely positive. However, the firm’s stock is still struggling to get this pharmaceutical company out of the oversold territory where it...
Read More
August 21, 2019
0
Amgen to Acquire Celgene's Product Otezla at $13.4 Billion
Amgen Agreement with Celgene for Otezla® In the News Amgen ( AMGN ) entered into an agreement with Celgene ( CELG ) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and...
Read More
August 26, 2019
0
Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced immune cell therapy
Regeneron Pharmaceuticals (REGN) and bluebird bio, Inc. (BLUE) announced a collaboration to apply their respective technology platforms to the discovery, development, and commercialization of novel immune cell therapies for cancer . The collaborators will specifically leverage Regeneron’s VelociSuite ® platform...
Read More
August 9, 2018
0
Aerie’s successful new confirmatory study for Rhopressa® was a necessity
Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa ® (netarsudil ophthalmic solution ) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This...
Read More
August 15, 2018
0
Why Moderna Stock Is Boosted in Today's Bad Stock Market Day
Coronavirus On January 7, 2020, a novel coronavirus ( 2019-nCoV ) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world....
Read More
January 27, 2020
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)